149 related articles for article (PubMed ID: 24276037)
21. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
Huang JB; Xue HM; Chen YY; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
[TBL] [Abstract][Full Text] [Related]
22. Outcome in children with pulmonary Langerhans cell Histiocytosis.
Braier J; Latella A; Balancini B; Castaños C; Rosso D; Chantada G; Ripoli M; Goldberg J
Pediatr Blood Cancer; 2004 Dec; 43(7):765-9. PubMed ID: 15390304
[TBL] [Abstract][Full Text] [Related]
23. Craniofacial involvement in Langerhans cell histiocytosis: A review of 44 cases at a single medical center.
Lin TE; Chu YY; Chang TY; Liao HT
J Plast Reconstr Aesthet Surg; 2023 Jul; 82():12-20. PubMed ID: 37148805
[TBL] [Abstract][Full Text] [Related]
24. Histiocytic syndromes in children.
Cetingül N; Oztop S; Kavakli K; Ozunan I; Nişli G; Hekimgil M
Turk J Pediatr; 1997; 39(3):287-94. PubMed ID: 9339106
[TBL] [Abstract][Full Text] [Related]
25. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
Minkov M
Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
[TBL] [Abstract][Full Text] [Related]
26. High serum osteopontin levels in pediatric patients with high risk Langerhans cell histiocytosis.
Oh Y; Morimoto A; Shioda Y; Imamura T; Kudo K; Imashuku S;
Cytokine; 2014 Dec; 70(2):194-7. PubMed ID: 25086462
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
[TBL] [Abstract][Full Text] [Related]
28. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.
Gadner H; Grois N; Pötschger U; Minkov M; Aricò M; Braier J; Broadbent V; Donadieu J; Henter JI; McCarter R; Ladisch S;
Blood; 2008 Mar; 111(5):2556-62. PubMed ID: 18089850
[TBL] [Abstract][Full Text] [Related]
29. Differentiating skin-limited and multisystem Langerhans cell histiocytosis.
Simko SJ; Garmezy B; Abhyankar H; Lupo PJ; Chakraborty R; Lim KP; Shih A; Hicks MJ; Wright TS; Levy ML; McClain KL; Allen CE
J Pediatr; 2014 Nov; 165(5):990-6. PubMed ID: 25441388
[TBL] [Abstract][Full Text] [Related]
30. Incidence of Langerhans cell histiocytosis in children: a population-based study.
Stålemark H; Laurencikas E; Karis J; Gavhed D; Fadeel B; Henter JI
Pediatr Blood Cancer; 2008 Jul; 51(1):76-81. PubMed ID: 18266220
[TBL] [Abstract][Full Text] [Related]
31. Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan.
Kudo K; Ohga S; Morimoto A; Ishida Y; Suzuki N; Hasegawa D; Nagatoshi Y; Kato S; Ishii E
Bone Marrow Transplant; 2010 May; 45(5):901-6. PubMed ID: 19767778
[TBL] [Abstract][Full Text] [Related]
32. Predictors of outcome in children with Langerhans cell histiocytosis.
Jubran RF; Marachelian A; Dorey F; Malogolowkin M
Pediatr Blood Cancer; 2005 Jul; 45(1):37-42. PubMed ID: 15768381
[TBL] [Abstract][Full Text] [Related]
33. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution.
Braier J; Chantada G; Rosso D; Bernaldez P; Amaral D; Latella A; Balancini B; Masautis A; Goldberg J
Pediatr Hematol Oncol; 1999; 16(5):377-85. PubMed ID: 10505313
[TBL] [Abstract][Full Text] [Related]
34. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group.
Haupt R; Nanduri V; Calevo MG; Bernstrand C; Braier JL; Broadbent V; Rey G; McClain KL; Janka-Schaub G; Egeler RM
Pediatr Blood Cancer; 2004 May; 42(5):438-44. PubMed ID: 15049016
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
Monsereenusorn C; Suwannaying K; Techavichit P; Sathitsamitphong L; Komvilaisak P; Rujkijyanont P; Seksarn P; Charoenkwan P; Pakakasama S
Int J Hematol; 2022 Apr; 115(4):563-574. PubMed ID: 35099760
[TBL] [Abstract][Full Text] [Related]
36. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study.
Duan MH; Han X; Li J; Zhang W; Zhu TN; Han B; Zhuang JL; Wang SJ; Cao XX; Cai HC; Chen M; Yang C; Zhou DB
Leuk Res; 2016 Mar; 42():43-6. PubMed ID: 26859782
[TBL] [Abstract][Full Text] [Related]
37. Merkel cell polyomavirus DNA sequences in peripheral blood and tissues from patients with Langerhans cell histiocytosis.
Murakami I; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Horie Y; Hayashi K; Imamura T; Morimoto A; Imashuku S; Gogusev J; Jaubert F; Takata K; Oka T; Yoshino T
Hum Pathol; 2014 Jan; 45(1):119-26. PubMed ID: 24321520
[TBL] [Abstract][Full Text] [Related]
38. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan.
Imamura T; Sato T; Shiota Y; Kanegane H; Kudo K; Nakagawa S; Nakadate H; Tauchi H; Kamizono J; Morimoto A
Int J Hematol; 2010 May; 91(4):646-51. PubMed ID: 20361277
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of children younger than 24 months with langerhans cell histiocytosis and bone involvement: a report from a single institution.
Kamath S; Arkader A; Jubran RF
J Pediatr Orthop; 2014 Dec; 34(8):825-30. PubMed ID: 25387157
[TBL] [Abstract][Full Text] [Related]
40. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study.
Titgemeyer C; Grois N; Minkov M; Flucher-Wolfram B; Gatterer-Menz I; Gadner H
Med Pediatr Oncol; 2001 Aug; 37(2):108-14. PubMed ID: 11496348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
